Kestrel Investment Management Corp Purchases New Shares in Haemonetics Corporation $HAE

Kestrel Investment Management Corp acquired a new position in Haemonetics Corporation (NYSE:HAE) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 101,800 shares of the medical instruments supplier’s stock, valued at approximately $4,961,000. Haemonetics makes up approximately 2.8% of Kestrel Investment Management Corp’s investment portfolio, making the stock its 14th biggest holding. Kestrel Investment Management Corp owned approximately 0.22% of Haemonetics at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Norges Bank bought a new position in shares of Haemonetics in the 2nd quarter worth about $36,822,000. SG Capital Management LLC increased its stake in shares of Haemonetics by 92.5% during the second quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock valued at $67,663,000 after purchasing an additional 435,660 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Haemonetics by 157.9% during the second quarter. AQR Capital Management LLC now owns 450,248 shares of the medical instruments supplier’s stock valued at $33,390,000 after purchasing an additional 275,683 shares during the last quarter. River Road Asset Management LLC grew its stake in shares of Haemonetics by 18.7% in the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock worth $122,586,000 after buying an additional 260,624 shares during the last quarter. Finally, ABN Amro Investment Solutions bought a new position in Haemonetics during the 3rd quarter valued at approximately $186,000. Institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on HAE. BTIG Research reissued a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a report on Friday, February 6th. Mizuho dropped their price target on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a research note on Friday, February 6th. Barrington Research set a $94.00 price objective on shares of Haemonetics in a research note on Friday, February 6th. CJS Securities upgraded shares of Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Finally, Needham & Company LLC downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $84.44.

Haemonetics Price Performance

NYSE HAE opened at $63.28 on Monday. The company has a 50-day moving average price of $70.13 and a 200-day moving average price of $64.19. Haemonetics Corporation has a 52 week low of $47.31 and a 52 week high of $87.32. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $2.94 billion, a P/E ratio of 17.43, a PEG ratio of 1.32 and a beta of 0.28.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.04. The business had revenue of $338.97 million for the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The company’s revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Equities research analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.